Cargando…

Role of clinical biomarkers in predicting the effectiveness of omalizumab

OBJECTIVE: To explore whether baseline clinical biomarkers and characteristics can be used to predict the responsiveness of omalizumab. METHODS: We retrospectively analyzed a cohort of patients with severe asthma who received omalizumab treatment and collected their baseline data and relevant labora...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qing, Li, Chunxiao, Wan, Jingxuan, Zhang, Mengyuan, Nong, Ying, Lin, Jiangtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164849/ https://www.ncbi.nlm.nih.gov/pubmed/37148201 http://dx.doi.org/10.1177/17534666231170821

Ejemplares similares

Artesunate inhibits airway remodeling in asthma via the MAPK signaling pathway
por: Zhang, Mengyuan, et al.
Publicado: (2023)

Prevalence of and risk factors for asthma among people aged 45 and older in China: a cross-sectional study
por: Wan, Jingxuan, et al.
Publicado: (2021)

Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis
por: Zhang, Yuan, et al.
Publicado: (2022)

Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
por: Pedersen, Nadja Højgaard, et al.
Publicado: (2023)

Omalizumab in Children
por: Licari, Amelia, et al.
Publicado: (2014)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history
por: Tabatabaian, Farnaz, et al.
Publicado: (2018)

Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab
por: Doan, Serge, et al.
Publicado: (2023)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Pediatric usage of Omalizumab: A promising one
por: Yu, Lin, et al.
Publicado: (2021)

The effect of COVID-19 on patients recieving omalizumab treatment
por: Sayaca, N., et al.
Publicado: (2023)

Effects of Omalizumab Treatment in Patients With Refractory Chronic Urticaria
por: Nam, Young-Hee, et al.
Publicado: (2012)

Omalizumab for urticaria treatment in clinical practice: a case series
por: Lesiak, Aleksandra, et al.
Publicado: (2018)

Omalizumab—A Review
por: Godse, Kiran, et al.
Publicado: (2015)

Omalizumab for chronic urticaria in Latin America
por: Wilches, Paul, et al.
Publicado: (2016)

Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma
por: Brooks, Elizabeth A, et al.
Publicado: (2019)

Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics
por: Yan, Huacheng, et al.
Publicado: (2023)

Expert consensus on the use of omalizumab in chronic urticaria in China()
por: Zhao, Zuotao, et al.
Publicado: (2021)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Cytokine Profiles of Chronic Urticaria Patients and The Effect of Omalizumab Treatment
por: Can Bostan, Ozge, et al.
Publicado: (2023)

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
por: Dekkers, Coco, et al.
Publicado: (2021)

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
por: de Brito, Marianne, et al.
Publicado: (2018)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Impact of Omalizumab in Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Poster 1002: Galectin-3 as predictive biomarker of airways remodeling modulation in omalizumab treated severe asthma patients
por: Mauri, Pierluigi, et al.
Publicado: (2014)

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria
por: Diluvio, Laura, et al.
Publicado: (2020)

Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level
por: Li, Bohou, et al.
Publicado: (2020)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

Effects of omalizumab therapy on peripheral nerve functions: short observational study
por: Yavuz, Goknur Ozaydın, et al.
Publicado: (2018)

Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months
por: Riccio, Anna Maria, et al.
Publicado: (2017)

Effects of omalizumab on chronic urticaria not responding to recommended therapy
por: Hébert, Jacques, et al.
Publicado: (2012)

Omalizumab in an allergology clinic: real life experience and future developments
por: Kupczyk, Maciej, et al.
Publicado: (2014)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Rapid clinical improvement of atopic dermatitis in an Omalizumab treated patient
por: Bormioli, Susanna, et al.
Publicado: (2019)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
por: Ashkenazi, Moshe, et al.
Publicado: (2018)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
por: Uzer, Fatih, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m8aeqf1jk5q9cfej5plm7prr2l